Sagimet director granted 39,567 stock options

Sagimet Biosciences Inc. granted director Kemble George a stock option covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share.

Rhea-AI Filing Summary

Sagimet Biosciences Inc. granted director Kemble George a stock option covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. The option expires on June 11, 2036 and represents 39,567 derivative shares held after this grant.

According to the award terms, the shares underlying this option vest in twelve equal monthly installments following June 12, 2026, conditioned on his continued service on each vesting date.

Insider Trade Summary

Grant/Award: 39,567 shares

Grant/Award 1 txn

Insider Kemble George

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	39,567	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 39,567 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option shares granted: 39,567 shares Exercise price: $6.48 per share Total derivative shares after grant: 39,567 shares +3 more

6 metrics

Option shares granted 39,567 shares Stock Option (Right to Buy) awarded to director Kemble George

Exercise price $6.48 per share Conversion or exercise price for the stock option

Total derivative shares after grant 39,567 shares Total shares underlying options following this transaction

Expiration date June 11, 2036 Option’s stated expiration date

Vesting schedule 12 equal monthly installments Vesting over twelve months following June 12, 2026

Vesting start reference date June 12, 2026 Installments vest monthly after this date, subject to continued service

Key Terms

Stock Option (Right to Buy), Series A Common Stock, exercise price, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Series A Common Stock financial

"underlying_security_title: "Series A Common Stock""

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

exercise price financial

"conversion_or_exercise_price: "6.4800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments"

expiration date financial

"expiration_date: "2036-06-11T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sagimet Biosciences director Kemble George receive in this SGMT filing?

Director Kemble George received a stock option award for 39,567 shares of Series A Common Stock at a $6.48 exercise price. This option is compensation-related and does not reflect an open-market stock purchase or sale.

How many Sagimet Biosciences (SGMT) shares are covered by the new option?

The new option covers 39,567 shares of Sagimet Biosciences Series A Common Stock. These shares are only issuable if the option is exercised in the future after they have vested under the award’s schedule.

What is the exercise price of Kemble George’s Sagimet Biosciences option grant?

The exercise price is $6.48 per share for the 39,567-share stock option. This means George must pay $6.48 for each share if he chooses to exercise the option once it has vested and become exercisable.

When do Kemble George’s Sagimet Biosciences options start vesting?

The shares underlying this option begin vesting after June 12, 2026. Vesting occurs in twelve equal monthly installments, and each installment requires Kemble George to remain in service through the applicable vesting date.

What is the expiration date of the Sagimet Biosciences (SGMT) option grant?

The option expires on June 11, 2036, giving up to roughly ten years from grant for potential exercise. Any shares not exercised by that date will no longer be available under this option award.

Is this Sagimet Biosciences transaction a market buy or sell of SGMT shares?

No, this transaction is a grant of stock options, not an open-market buy or sell. It is a compensation award that may lead to future share acquisitions only if the options vest and are exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kemble George

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO CALIFORNIA 94402

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.48	06/12/2026		A		39,567		(1)	06/11/2036	Series A Common Stock	39,567	$0	39,567	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)